8-K 1 c79747e8vk.txt FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ---------------- FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2003 MANHATTAN PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-27282 36-3898269 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.) 787 Seventh Avenue, 48th Floor New York, New York 10019 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (212) 554-4525 (Former Name or Former Address, if Changed Since Last Report) ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE. The Registrant's press release dated September 18, 2003, which is attached to this Current Report on Form 8-K as Exhibit 99.1, is incorporated by reference herein. ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS. (c) Exhibits 99.1 Company's press release dated September 18, 2003. SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANHATTAN PHARMACEUTICALS, INC. Date: September 23, 2003 By: /s/ Nicholas J. Rossettos ------------------------------------ Nicholas J. Rossettos Chief Operating Officer and Chief Financial Officer 2 EXHIBIT INDEX 99.1 Registrant's Press Release dated September 18, 2003.